Werewolf Therapeutics Appoints Steven Bloom as Chief Business Officer
Werewolf Therapeutics (Nasdaq: HOWL) has appointed Steven Bloom as Chief Business Officer, bringing over 35 years of life sciences industry experience. Bloom joins from Vincerx Pharma, where he previously served as CBO, and has held senior positions at companies including Ziopharm Oncology, Verastem Oncology, and Eli Lilly.
The company is approaching key milestones in 2025, including interim dose expansion data from the WTX-124 Phase 1/1b clinical trial, which has shown durable confirmed responses in cancer patients. The trial results are expected to guide discussions with regulators on potential registrational pathways.
As part of his compensation package, Bloom received a stock option grant for 201,720 shares, vesting over four years, with 25% vesting after the first year and the remainder monthly over three years.
Werewolf Therapeutics (Nasdaq: HOWL) ha nominato Steven Bloom Chief Business Officer, portando con sé oltre 35 anni di esperienza nell'industria delle scienze della vita. Bloom arriva da Vincerx Pharma, dove ha ricoperto il ruolo di CBO, e ha occupato posizioni di rilievo in aziende come Ziopharm Oncology, Verastem Oncology ed Eli Lilly.
L'azienda si prepara a raggiungere traguardi importanti nel 2025, tra cui i dati preliminari sull'espansione della dose della fase 1/1b dello studio clinico WTX-124, che ha mostrato risposte confermate e durature in pazienti oncologici. I risultati dello studio guideranno le discussioni con le autorità regolatorie sulle possibili vie di registrazione.
Come parte del suo pacchetto retributivo, Bloom ha ricevuto un'opzione su azioni per 201.720 titoli, con un vesting distribuito su quattro anni: il 25% dopo il primo anno e il resto mensilmente nei successivi tre anni.
Werewolf Therapeutics (Nasdaq: HOWL) ha nombrado a Steven Bloom como Chief Business Officer, aportando más de 35 años de experiencia en la industria de ciencias de la vida. Bloom proviene de Vincerx Pharma, donde anteriormente fue CBO, y ha ocupado cargos senior en empresas como Ziopharm Oncology, Verastem Oncology y Eli Lilly.
La compañía se acerca a hitos clave en 2025, incluyendo datos interinos de expansión de dosis del ensayo clínico de fase 1/1b WTX-124, que ha mostrado respuestas confirmadas y duraderas en pacientes con cáncer. Se espera que los resultados del ensayo guíen las conversaciones con los reguladores sobre posibles vías de registro.
Como parte de su paquete de compensación, Bloom recibió una concesión de opciones sobre acciones por 201,720 títulos, vesting durante cuatro años, con un 25% liberado tras el primer año y el resto mensualmente durante los siguientes tres años.
Werewolf Therapeutics(나스닥: HOWL)는 35년 이상의 생명과학 산업 경력을 보유한 스티븐 블룸을 최고사업책임자(CBO)로 임명했습니다. 블룸은 이전에 Vincerx Pharma에서 CBO로 근무했으며 Ziopharm Oncology, Verastem Oncology, Eli Lilly 등 여러 회사에서 고위직을 역임했습니다.
회사는 2025년에 중요한 이정표를 앞두고 있으며, 암 환자에서 지속적인 확인된 반응을 보인 WTX-124 1/1b상 임상시험의 중간 용량 확대 데이터를 포함합니다. 이 임상 결과는 규제 당국과의 등록 경로 논의를 안내할 것으로 기대됩니다.
보상 패키지의 일환으로 블룸은 201,720주의 주식 옵션을 받았으며, 4년에 걸쳐 권리 취득이 이루어집니다. 첫 해에 25%가 취득되고, 나머지는 이후 3년 동안 매월 취득됩니다.
Werewolf Therapeutics (Nasdaq : HOWL) a nommé Steven Bloom Chief Business Officer, apportant plus de 35 ans d'expérience dans l'industrie des sciences de la vie. Bloom rejoint l'entreprise en provenance de Vincerx Pharma, où il a précédemment occupé le poste de CBO, et a occupé des postes de direction dans des sociétés telles que Ziopharm Oncology, Verastem Oncology et Eli Lilly.
L'entreprise s'approche d'étapes clés en 2025, notamment les données intermédiaires d'expansion de dose de l'essai clinique de phase 1/1b WTX-124, qui a montré des réponses confirmées durables chez des patients atteints de cancer. Les résultats de l'essai devraient orienter les discussions avec les autorités réglementaires sur les voies potentielles d'enregistrement.
Dans le cadre de son package de rémunération, Bloom a reçu une attribution d'options d'achat d'actions pour 201 720 actions, acquises sur quatre ans, avec 25 % acquis après la première année et le reste mensuellement sur les trois années suivantes.
Werewolf Therapeutics (Nasdaq: HOWL) hat Steven Bloom zum Chief Business Officer ernannt, der über 35 Jahre Erfahrung in der Life-Sciences-Branche mitbringt. Bloom kommt von Vincerx Pharma, wo er zuvor als CBO tätig war, und hatte leitende Positionen bei Unternehmen wie Ziopharm Oncology, Verastem Oncology und Eli Lilly inne.
Das Unternehmen steht vor wichtigen Meilensteinen im Jahr 2025, darunter vorläufige Daten zur Dosissteigerung aus der WTX-124 Phase 1/1b klinischen Studie, die anhaltende bestätigte Ansprechraten bei Krebspatienten gezeigt hat. Die Studienergebnisse sollen die Gespräche mit den Regulierungsbehörden über mögliche Zulassungswege leiten.
Im Rahmen seines Vergütungspakets erhielt Bloom eine Aktienoptionszuteilung für 201.720 Aktien, die über vier Jahre vestet, wobei 25 % nach dem ersten Jahr und der Rest monatlich über die folgenden drei Jahre vestet.
- WTX-124 clinical trial showing durable confirmed responses in cancer patients
- Appointment of experienced CBO with 35+ years industry expertise
- Advancing PREDATOR platform development for multiple therapeutic modalities
- None.
WATERTOWN, Mass., April 17, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions, today announced the appointment of Steven Bloom as Chief Business Officer. Mr. Bloom brings more than 35 years of experience in the life sciences industry leading teams in corporate development, commercial planning, corporate affairs, and strategic consulting.
“Steve brings deep experience in strategic transactions to Werewolf at this critical time,” said Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf Therapeutics. “Werewolf is approaching important inflection points this year with interim dose expansion data from the WTX-124 Phase 1/1b clinical trial expected to guide discussions with regulators on potential registrational pathways, and our PREDATOR platform continuing to develop novel molecules for oncology, immunology and additional therapeutic modalities.”
Mr. Bloom joins Werewolf from Vincerx Pharma, Inc., where he served as Chief Business Officer. During his time at Vincerx as a member of the executive leadership team focused on business development, commercial assessment, and corporate strategy, Mr. Bloom led a program and platform valuation project and worked with the executive team on multiple transaction initiatives to help stabilize the company. Previously, he worked at several biotechnology companies including Ziopharm Oncology, Inc., Verastem Oncology, and Vavotar Life Sciences LLC, where he led multiple business development transactions. Mr. Bloom also held senior roles at Eli Lilly and Company earlier in his career where he led sales and marketing, patient advocacy, and corporate affairs functions.
“Werewolf is positioning itself to change the way cancer is treated through its novel immunotherapy technology designed to attack the tumor while minimizing patient side effects,” said Mr. Bloom. “Werewolf’s lead program WTX-124 has demonstrated durable confirmed responses in patients with cancer, and Werewolf has continued to develop a deep and diverse pipeline using its PREDATOR technology. I am thrilled to join this experienced team and look forward to working with Werewolf to advance its products.”
Mr. Bloom graduated from Northeastern University School of Pharmacy and has been an American Cancer Society Road to Recovery driver since 2008. Mr. Bloom is currently Chair of the Board of Directors of the CLL Society, a nonprofit organization that addresses the unmet needs of the chronic lymphocytic leukemia and small lymphocytic lymphoma community through patient education, advocacy, support, and research.
In connection with Mr. Bloom’s appointment, Werewolf’s board of directors approved a stock option grant to Mr. Bloom as an inducement material to his entering into employment with Werewolf in accordance with Nasdaq Listing Rule 5635(c)(4). The stock option provides for the purchase of up to 201,720 shares of Werewolf common stock at an exercise price equal to the closing price of the Werewolf common stock on May 1, 2025, the effective date of grant. The stock option has a ten-year term and vests as to
About Werewolf Therapeutics:
Werewolf Therapeutics, Inc., is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions. The Company is leveraging its proprietary PREDATOR® platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Werewolf’s INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. The Company’s most advanced clinical stage product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and Interleukin-12 (IL-12) INDUKINE molecules, respectively, for the treatment of solid tumors. Werewolf is advancing WTX-124 in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor and WTX-330 in multiple tumor types or Non-Hodgkin Lymphoma as a single agent. To learn more visit www.werewolftx.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release, including statements regarding Werewolf’s strategy, future operations, prospects, plans, and objectives of management; the expected timeline for the preclinical and clinical development of product candidates and the availability of data from such preclinical and clinical development; the potential activity and efficacy of product candidates in preclinical studies and clinical trials; and the anticipated safety profile of product candidates constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words “aim,” “anticipate,” “believe,” “contemplate,” “continue,” “could,” “design,” “designed to,” “engineered,” “estimate,” “expect,” “goal,” “intend,” “may,” “might,” “objective,” “ongoing,” “plan,” “positioning itself to,” “potential,” “predict,” “project,” “promise,” “should,” “target,” “will,” “working to,” or “would,” or the negative of these terms, or other comparable terminology are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including: uncertainties inherent in the development of product candidates, including the conduct of research activities, and the initiation and completion of preclinical studies and clinical trials; uncertainties as to the availability and timing of results from preclinical studies and clinical trials; the timing of and the Company’s ability to submit and obtain regulatory approval for investigational new drug applications; whether results from preclinical studies will be predictive of the results of later preclinical studies and clinical trials; whether preliminary or interim data from a clinical trial will be predictive of the future results of the trial and future clinical trials; as well as the risks and uncertainties identified in the “Risk Factors” section of the Company’s most recent Form 10-K filed with the Securities and Exchange Commission (SEC), and in subsequent filings the Company may make with the SEC. In addition, the forward-looking statements included in this press release represent the Company’s views as of the date of this press release. The Company anticipates that subsequent events and developments will cause its views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this press release.
WEREWOLF®, the WEREWOLF logo, PREDATOR®, INDUKINE™ and other Werewolf trademarks, service marks, graphics and logos are trade names, trademarks or registered trademarks of Werewolf Therapeutics, Inc., in the United States or other countries. All rights reserved.
Investor Contact
Dan Ferry
LifeSci Advisors
617.430.7576
daniel@lifesciadvisors.com
Media Contact:
Amanda Sellers
Deerfield Group
301.332.5574
amanda.sellers@deerfieldgroup.com
Company Contact:
Timothy Trost
Chief Financial Officer
Werewolf Therapeutics
ttrost@werewolftx.com
FAQ
What progress has Werewolf Therapeutics (HOWL) made with its WTX-124 cancer treatment?
What is the vesting schedule for Steven Bloom's stock options at Werewolf Therapeutics (HOWL)?
How is Werewolf Therapeutics (HOWL) developing cancer treatments differently?
What experience does Steven Bloom bring to Werewolf Therapeutics (HOWL)?
